New combo therapy aims to control blood cancer relapse after transplant
NCT ID NCT05226455
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 20 times
Summary
This study tests a combination of two drugs (venetoclax and azacitidine) plus donor immune cells in people whose myelodysplastic syndrome or acute myeloid leukemia has returned after a stem cell transplant. The goal is to find the safest dose and see if this approach can improve response. About 55 adults with relapsed disease are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Hôtel Dieu
Nantes, 44093, France
-
CHU d'Angers
Angers, 49933, France
-
CHU de Grenoble
Grenoble, 38043, France
-
CHU de Haut-Lévèque
Pessac, 33604, France
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Hospitalier Lyon-Sud
Pierre-Bénite, 69495, France
-
Hôpital Dupuytren
Limoges, 87042, France
-
Hôpital Saint louis
Paris, 75010, France
-
Hôpital Saint-Eloi
Montpellier, 34295, France
-
Hôpital l'Archet I
Nice, 06200, France
-
IUCT Oncopole
Toulouse, 31059, France
Conditions
Explore the condition pages connected to this study.